Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALT 
Altimmune Inc (ALT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: ALT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.44
1 Year Target Price $16.44
| 5 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.99% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 353.03M USD | Price to earnings Ratio - | 1Y Target Price 16.44 |
Price to earnings Ratio - | 1Y Target Price 16.44 | ||
Volume (30-day avg) 9 | Beta 0.06 | 52 Weeks Range 2.90 - 11.16 | Updated Date 10/14/2025 |
52 Weeks Range 2.90 - 11.16 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -458440% |
Management Effectiveness
Return on Assets (TTM) -32.43% | Return on Equity (TTM) -55.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 179595004 | Price to Sales(TTM) 17651.45 |
Enterprise Value 179595004 | Price to Sales(TTM) 17651.45 | ||
Enterprise Value to Revenue 8979.75 | Enterprise Value to EBITDA -4.2 | Shares Outstanding 88257253 | Shares Floating 87577672 |
Shares Outstanding 88257253 | Shares Floating 87577672 | ||
Percent Insiders 0.78 | Percent Institutions 43.11 |
Upturn AI SWOT
Altimmune Inc
Company Overview
History and Background
Altimmune Inc. was founded in 1997. Originally named Vaxin Inc., the company has focused on developing novel immunotherapeutic products and vaccines. It rebranded as Altimmune in 2011. The company has evolved through various clinical trials and partnerships in its pursuit of innovative therapies.
Core Business Areas
- Obesity and NASH Therapeutics: Development of peptide-based therapeutics targeting obesity, NASH (nonalcoholic steatohepatitis), and related metabolic diseases. Their lead product candidate, pemvidutide, is a GLP-1R/glucagon dual receptor agonist.
- Vaccines: Development of single-dose intranasal vaccines for respiratory diseases, including influenza and COVID-19.
Leadership and Structure
Dr. Vipin K. Garg is the President and CEO. The organizational structure includes departments focused on research and development, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Pemvidutide: A GLP-1R/glucagon dual receptor agonist in clinical development for obesity and NASH. Currently in Phase 2 clinical trials. Market share is currently 0% as it is not yet approved for commercial use. Competitors include Novo Nordisk (Wegovy, Ozempic), Eli Lilly (Mounjaro), and other companies developing GLP-1 receptor agonists or similar therapies.
- NasalFlu/AdCOVID: Single-dose intranasal vaccines targeting influenza and COVID-19, respectively. Both programs are in clinical stages of development but AdCOVID has been paused. Market share is currently 0% as neither is approved for commercial use. Competitors include flu vaccine manufacturers such as GSK (GSK), Sanofi (SNY), and Moderna (MRNA) for mRNA COVID vaccines.
Market Dynamics
Industry Overview
The pharmaceutical industry is experiencing growth in obesity, NASH and vaccines. Innovation and speed to market is vital for success.
Positioning
Altimmune positions itself as an innovator in metabolic disease and vaccine development, focusing on differentiated mechanisms of action and convenient delivery methods. Its competitive advantage lies in its dual-receptor agonist approach for metabolic diseases and its intranasal vaccine technology.
Total Addressable Market (TAM)
The obesity market is projected to reach hundreds of billions of dollars. The NASH market is also expected to grow significantly. Altimmune is positioned to capture a share of these markets pending successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel dual-receptor agonist approach (pemvidutide)
- Intranasal vaccine technology
- Experienced leadership team
- Strong patent portfolio
Weaknesses
- Reliance on clinical trial success
- Limited revenue generation
- High cash burn rate
- Competition from established pharmaceutical companies
Opportunities
- Positive clinical trial results for pemvidutide
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Government funding and grants
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from new entrants
- Economic downturn
Competitors and Market Share
Key Competitors
- NVO
- LLY
- GILD
Competitive Landscape
Altimmune faces intense competition from established pharmaceutical companies with significant resources and approved products. Altimmune's advantages lie in its novel mechanisms of action, but it must demonstrate superior efficacy and safety in clinical trials to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been largely driven by clinical program advancement and fundraising activities.
Future Projections: Future growth depends on the success of clinical trials. Analyst estimates vary widely but generally anticipate significant revenue potential if pemvidutide is approved.
Recent Initiatives: Recent initiatives include the continued enrollment and data readout of their Phase 2 clinical trials for pemvidutide, focusing on obesity and NASH.
Summary
Altimmune is a clinical-stage biotechnology company with promising drug candidates in the obesity/NASH and vaccine spaces. Pemvidutide holds significant potential in addressing metabolic diseases. The company's success hinges on positive clinical trial outcomes, navigating regulatory hurdles, and securing strategic partnerships. The risk is high, but the potential reward is significant if they can bring a successful product to market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial professional. Financial data is estimated and should not be considered precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Altimmune Inc
Exchange NASDAQ | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2005-10-06 | President, CEO & Director Dr. Vipin K. Garg Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://altimmune.com |
Full time employees 59 | Website https://altimmune.com | ||
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.